Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female with an intact uterus with lifetime history of 0-4 sexual partners~Exclusion Criteria:~* Prior Human Papillomavirus Vaccine (HPV) vaccination;~* Prior abnormal paps;~* Prior history of genital warts

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).